Acelyrin (Acelyrin) Interest Expense : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Acelyrin Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Acelyrin's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Acelyrin's Operating Income for the three months ended in Mar. 2024 was $ -82.77 Mil. Acelyrin's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Acelyrin's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Acelyrin Interest Expense Historical Data

The historical data trend for Acelyrin's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acelyrin Interest Expense Chart

Acelyrin Annual Data

Trend

Dec21

Dec22

Dec23

Interest Expense

Acelyrin Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial					-	-	-	-	-

Acelyrin Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Acelyrin (NAS:SLRN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Acelyrin's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-82.77 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $1.13 Mil.

Acelyrin's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate Acelyrin's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Acelyrin Inc has enough cash to cover all of its debt. Its financial situation is stable.

Acelyrin (Acelyrin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acelyrin Inc (NAS:SLRN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4149 Liberty Canyon Road, Agoura Hills, CA, USA, 91301

Website

https://www.acelyrin.com

Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.

Executives

Shao-lee Lin	director, officer: Chief Executive Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Gil M Labrucherie	officer: Interim CFO	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Beth C Seidenberg	director, 10 percent owner
Henry O Gosebruch	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Mardi Dier	officer: CFO and CBO	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Mina Kim	officer: Chief Legal & Admin. Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Ronald Oyston	officer: Chief People Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Paul Peloso	officer: Chief Medical Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Daniel J. Becker	director	C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Westlake Biopartners Fund Ii, L.p.	10 percent owner	3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361
Ayurmaya Capital Management Company, Lp	director, 10 percent owner, other: See Remarks	1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Sean E Harper	10 percent owner	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Melanie Gloria	officer: Chief Operating Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Westlake Biopartners Gp Ii, Llc	10 percent owner	3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361